Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma
- 1 March 2015
- journal article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 33 (3) , 113.e1-113.e7
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Intratumoral heterogeneity in kidney cancerNature Genetics, 2014
- Evolving therapeutic targets in renal cell carcinomaCurrent Opinion in Oncology, 2013
- Pancreatic metastases from renal cell carcinoma: The state of the artWorld Journal of Gastroenterology, 2011
- Prognostic role of global DNA‐methylation and histone acetylation in pT1a clear cell renal carcinoma in partial nephrectomy specimensJournal of Cellular and Molecular Medicine, 2008
- Advanced Renal Cell CarcinomaDrugs, 2007
- Biology and Clinical Development of Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell CarcinomaJournal of Clinical Oncology, 2005
- Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2005
- The von Hippel-Lindau Tumor Suppressor Gene Product Interacts with Sp1 To Repress Vascular Endothelial Growth Factor Promoter ActivityMolecular and Cellular Biology, 1997
- Mutations of the VHL tumour suppressor gene in renal carcinomaNature Genetics, 1994
- Identification of the von Hippel-Lindau Disease Tumor Suppressor GeneScience, 1993